Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors’ reply

D. Logunov, I. Dolzhikova, A. Tukhvatullin, D. Shcheblyakov,

2021

https://doi.org/10.1016/S0140-6736(20)31970-X

Цитирование

Об авторах

D. Logunov
N F Gamaleya National Research Centre for Epidemiology and Microbiology, Moscow, 123098, Russian Federation
I. Dolzhikova
A. Tukhvatullin
D. Shcheblyakov

Название журнала

Том

Выпуск

Страницы

Ключевые слова

adenovirus vaccine; immunoglobulin G; rad 26; rad 5; SARS-CoV-2 vaccine; unclassified drug; COVID-19 vaccine; virus vaccine; antibody response; antibody titer; blood sampling; CD4+ T lymphocyte; CD8+ T lymphocyte; cell count; cell proliferation; coronavirus disease 2019; cross reaction; disease severity; drug efficacy; drug information; drug safety; enzyme linked immunosorbent assay; fever; follow up; freeze drying; human; humoral immunity; immune response; immunization; immunogenicity; Letter; lymphocyte percentage; optical density; phase 1 clinical trial (topic); phase 2 clinical trial (topic); polymerase chain reaction; priority journal; Russian Federation; sample size; Betacoronavirus; Coronavirus infection; pandemic; virus pneumonia; Betacoronavirus; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Russia; Viral Vaccines

Издатель

Тип документа

Источник